Read our latest updates & insights

Study finds mAbxienxe’s biosimilar rituximab candidate RTXM83 is not inferior to the reference drug in terms of efficacy.

Mylan launches Hulio® in Spain following EC approval in September 2018.

Catalyst Biosciences announce eptacog alfa biosimilar met primary endpoints in Ph II trials.

A new study reveals rituximab may be effective in managing mixed cryoglobulinemic vasculitis.

Samsung and Genentech settle patent dispute, allowing for the sale of Samsung’s Ontruzant®.

Prestige announces agreements with Pharmapark and Mundipharma for the supply and commercialisation of Tuznue® . An agreement reached with Pharmapark allows for supply and commercialisation in Russia, while the agreement with Mundipharma grants an exclusive license and suppl...

Amgen withdraws its Marketing Authorisation application for biosimilar infliximab ABP710, citing a change in product strategy.

Shanghai Biomabs commences Ph I trials of biosimilar denosumab candidate.

Study reveals outcomes for the use of filgrastim in stem cell mobilisation prior to transplant, recording similar outcomes for tbo-filgrastim, the reference drug and biosimilar filgrastim (Zarxio).

FDA approves Pfizer’s bevacizumab biosimilar, Zirabev® for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent gliobastoma; metastatic renal cell carcinoma; and persi...